Preclinical studies have suggested the potential role of newer glucose-lowering drugs, including dipeptidyl peptidase (DPP-4) inhibitors, GLP-1 RAs and sodium glucose co-transporter-2 (SGLT-2) inhibitors in protecting humans against cognitive decline. This evidence concerns the gene GCG and Mental deterioration.